HOST - DAPT Duration According the Bleeding Risk (HOST-BR)
Coronary Artery Disease, Acute Myocardial Infarction, Stable Angina
About this trial
This is an interventional treatment trial for Coronary Artery Disease focused on measuring percutenous coronary intervention, dual antiplatelet therapy, bleeding risk
Eligibility Criteria
Inclusion Criteria: The patient agrees to participate in this study by signing the informed consent form. Alternatively, a legally authorized patient representative may agree to the patient's participation in this study and sign the informed consent form. The patient in whom the Bleeding Risk (according to the ARC-HBR classification) can be calculated. The patient has a working diagnosis of coronary artery disease which has been treated with percutaneous coronary intervention. Exclusion Criteria: Hypersensitivity to aspirin or P2Y12 inhibitors Patients in whom coroanry artery disease has been decided to be medically managed without a coronary stent. Positive pregnancy test or is known to be pregnant Any other reason the investigator deems the subject to be unsuitable for the study (e.g., Any life-threatening condition with life expectancy less than 6months, etc.)
Sites / Locations
- Seoul National University HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Experimental
Active Comparator
Experimental
Active Comparator
HBR - 1M DAPT
HBR - 3M DAPT
LBR - 12M DAPT
LBR - 3M DAPT
Patients who receive percutaneous coronary intervention for coronary artery disease, and who have High bleeding risk (defined according to the ARC-HBR criteria) will be randomized to 1 month or 3 month DAPT duration.
Patients who receive percutaneous coronary intervention for coronary artery disease, and who have High bleeding risk (defined according to the ARC-HBR criteria) will be randomized to 1 month or 3 month DAPT duration.
Patients who receive percutaneous coronary intervention for coronary artery disease, and who do NOT have High bleeding risk (defined according to the ARC-HBR criteria) will be randomized to 3 month or 12 month DAPT duration.
Patients who receive percutaneous coronary intervention for coronary artery disease, and who do NOT have High bleeding risk (defined according to the ARC-HBR criteria) will be randomized to 3 month or 12 month DAPT duration.